drugset / Trial / NCT01353508

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

NCT01353508

Phase 2 Completed 32 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

Assess mechanism of action of LCZ696 related to sodium excretion.

Timeline

Start
2011-03
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 200 mg
Subject LCZ696 Unknown 400 mg
Subject Valsartan Small molecule 160 mg
Subject Valsartan Small molecule 320 mg

Indications